









Markets
/
Stocks
/
nasdaq-plrx
/

Pliant Therapeutics Inc

PLRX

1.140USD

+0.050+4.59%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

70.05MMarket Cap

LossP/E TTM



Pliant Therapeutics Inc

1.140

+0.050+4.59%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pliant Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Pliant Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.25.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pliant Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

113 / 159

Overall Ranking

348 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pliant Therapeutics Inc Highlights

StrengthsRisks

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.40, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.26M shares, decreasing 40.71% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 107.10K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.11.

Analyst Rating

Based on 7 analysts

Hold

Current Rating

3.250

Target Price

+198.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Pliant Therapeutics Inc is 5.80, ranking 150 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.80

Change



Financials

5.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Pliant Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Pliant Therapeutics Inc is 7.01, ranking 104 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.40, which is -14.69% below the recent high of -0.34 and -3007.12% above the recent low of -12.35.

Score

Industry at a Glance

Previous score

7.01

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Pliant Therapeutics Inc is 6.00, ranking 135 out of 159 in the Pharmaceuticals industry. The average price target is 3.50, with a high of 4.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Hold

Current Rating

3.250

Target Price

+198.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Pliant Therapeutics Inc

PLRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Pliant Therapeutics Inc is 3.79, ranking 150 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.32 and the support level at 1.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.64

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

36.397

Neutral

STOCH(KDJ)(9,3,3)

14.498

Oversold

ATR(14)

0.062

High Vlolatility

CCI(14)

-122.390

Sell

Williams %R

81.481

Oversold

TRIX(12,20)

-0.331

Sell

StochRSI(14)

73.991

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.161

Sell

MA10

1.206

Sell

MA20

1.251

Sell

MA50

1.288

Sell

MA100

1.439

Sell

MA200

1.462

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Pliant Therapeutics Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.04%, representing a quarter-over-quarter decrease of 0.44%. The largest institutional shareholder is Steven Cohen, holding a total of 4.34M shares, representing 7.06% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

6.00M

+0.06%

Woodline Partners LP

4.50M

+91.81%

Point72 Asset Management, L.P.

Star Investors

4.34M

Morgan Stanley & Co. LLC

3.50M

+75.33%

Citadel Advisors LLC

2.34M

-0.70%

Blue Owl Capital Holdings LP

2.97M

The Vanguard Group, Inc.

Star Investors

2.78M

-7.54%

Acadian Asset Management LLC

2.37M

+45.33%

J.P. Morgan Securities LLC

2.13M

+8.76%

Two Sigma Investments, LP

1.86M

+148.96%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pliant Therapeutics Inc is 2.82, ranking 117 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.